Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome Get access Arrow

In an exploratory trial treating “long COVID” with the C-C chemokine receptor 5 (CCR5)-binding antibody leronlimab, scientists observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants.